Press Releases

18 August 2020

Launch of the CARE consortia funded by the EU IMI program

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

27 January 2016

Launch of the EHVA consortia funded by the EU H2020 program

The European HIV Vaccine Alliance (EHVA) is a project funded by EU H2020 program. Its primary objective is to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. EuroVacc provides the support in the scientific project management.

16 February 2005

Start of the EV02 trial in Lausanne and London

EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.

7 June 2004

Results from EV01 trial in Lausanne and London

The results from the EV01 trial, to evaluate and safety and immunogenicity of NYVAC-C, showed that the vaccine is well tolerated and vaccine-induced T-cell responses were observed in 45% of the vaccine recipients.

30 July 2003

Start of the EV01 trial in Lausanne and London

EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.